Literature DB >> 19855166

ATX-LPA receptor axis in inflammation and cancer.

Shuying Liu1, Mandi Murph, Nattapon Panupinthu, Gordon B Mills.   

Abstract

Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) mediates a plethora of physiological and pathological activities via interactions with a series of high affinity G protein-coupled receptors (GPCR). Both LPA receptor family members and autotaxin (ATX/LysoPLD), the primary LPA-producing enzyme, are aberrantly expressed in many human breast cancers and several other cancer lineages. Using transgenic mice expressing either an LPA receptor or ATX, we recently demonstrated that the ATX-LPA receptor axis plays a causal role in breast tumorigenesis and cancer-related inflammation, further validating the ATX-LPA receptor axis as a rich therapeutic target in cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855166      PMCID: PMC4166520          DOI: 10.4161/cc.8.22.9937

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  115 in total

1.  A 1,536-well [(35)S]GTPgammaS scintillation proximity binding assay for ultra-high-throughput screening of an orphan galphai-coupled GPCR.

Authors:  Eric N Johnson; Xiaoqing Shi; Jason Cassaday; Marc Ferrer; Berta Strulovici; Priya Kunapuli
Journal:  Assay Drug Dev Technol       Date:  2008-06       Impact factor: 1.738

2.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

Authors:  Lauren P Saunders; Amy Ouellette; Russ Bandle; William Chozen Chang; Hongwen Zhou; Raj N Misra; Enrique M De La Cruz; Demetrios T Braddock
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

3.  Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E(2) release via C/EBPbeta in human bronchial epithelial cells.

Authors:  Donghong He; Viswanathan Natarajan; Randi Stern; Irina A Gorshkova; Julian Solway; Ernst Wm Spannhake; Yutong Zhao
Journal:  Biochem J       Date:  2008-05-15       Impact factor: 3.857

Review 4.  Therapeutic potential of autotaxin/lysophospholipase d inhibitors.

Authors:  Lorenzo Federico; Zehra Pamuklar; Susan S Smyth; Andrew J Morris
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

Review 5.  Two pathways for lysophosphatidic acid production.

Authors:  Junken Aoki; Asuka Inoue; Shinichi Okudaira
Journal:  Biochim Biophys Acta       Date:  2008-06-24

Review 6.  Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.

Authors:  Mandi M Murph; Giang H Nguyen; Harish Radhakrishna; Gordon B Mills
Journal:  Biochim Biophys Acta       Date:  2008-04-29

7.  Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor.

Authors:  Masanori Murakami; Akira Shiraishi; Kenichi Tabata; Norihisa Fujita
Journal:  Biochem Biophys Res Commun       Date:  2008-05-06       Impact factor: 3.575

8.  Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma.

Authors:  Akiko Masuda; Kazuhiro Nakamura; Koji Izutsu; Koji Igarashi; Ryunosuke Ohkawa; Masahiro Jona; Katsumi Higashi; Hiromitsu Yokota; Shinichi Okudaira; Tatsuya Kishimoto; Takuro Watanabe; Yukako Koike; Hitoshi Ikeda; Yasushi Kozai; Mineo Kurokawa; Junken Aoki; Yutaka Yatomi
Journal:  Br J Haematol       Date:  2008-08-15       Impact factor: 6.998

9.  alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.

Authors:  Peng Cui; William F McCalmont; Jose L Tomsig; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem       Date:  2007-12-04       Impact factor: 3.641

Review 10.  Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer.

Authors:  Carlo V Hojilla; Geoffrey A Wood; Rama Khokha
Journal:  Breast Cancer Res       Date:  2008-03-31       Impact factor: 6.466

View more
  56 in total

1.  Depot-specific regulation of autotaxin with obesity in human adipose tissue.

Authors:  Chloé Rancoule; Rodolphe Dusaulcy; Karine Tréguer; Sandra Grès; Charlotte Guigné; Didier Quilliot; Philippe Valet; Jean Sébastien Saulnier-Blache
Journal:  J Physiol Biochem       Date:  2012-05-27       Impact factor: 4.158

2.  Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.

Authors:  Sudeepti S Kuppa; Wei Jia; Shuying Liu; Ha Nguyen; Susan S Smyth; Gordon B Mills; Kevin K Dobbin; William J Hardman; Mandi M Murph
Journal:  Cancer Lett       Date:  2018-05-31       Impact factor: 8.679

3.  Endosomal H2O2 production leads to localized cysteine sulfenic acid formation on proteins during lysophosphatidic acid-mediated cell signaling.

Authors:  Chananat Klomsiri; LeAnn C Rogers; Laura Soito; Anita K McCauley; S Bruce King; Kimberly J Nelson; Leslie B Poole; Larry W Daniel
Journal:  Free Radic Biol Med       Date:  2014-03-21       Impact factor: 7.376

4.  Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Authors:  Shih-Chi Su; Xiaoxiao Hu; Patrick A Kenney; Megan M Merrill; Kara N Babaian; Xiu-Ying Zhang; Tapati Maity; Shun-Fa Yang; Xin Lin; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

5.  S100A8/A9 activate key genes and pathways in colon tumor progression.

Authors:  Mie Ichikawa; Roy Williams; Ling Wang; Thomas Vogl; Geetha Srikrishna
Journal:  Mol Cancer Res       Date:  2011-01-12       Impact factor: 5.852

6.  Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Authors:  Mandi M Murph; Guowei W Jiang; Molly K Altman; Wei Jia; Duy T Nguyen; Jada M Fambrough; William J Hardman; Ha T Nguyen; Sterling K Tran; Ali A Alshamrani; Damian Madan; Jianxing Zhang; Glenn D Prestwich
Journal:  Bioorg Med Chem       Date:  2015-07-02       Impact factor: 3.641

Review 7.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

8.  Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice.

Authors:  Lorenzo Federico; Hongmei Ren; Paul A Mueller; Tao Wu; Shuying Liu; Jelena Popovic; Eric M Blalock; Manjula Sunkara; Huib Ovaa; Harald M Albers; Gordon B Mills; Andrew J Morris; Susan S Smyth
Journal:  Mol Endocrinol       Date:  2012-04-03

9.  Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.

Authors:  Hadil Onallah; Liora Jacobs Catane; Claes G Tropé; Thea E Hetland Falkenthal; Reuven Reich; Ben Davidson
Journal:  Virchows Arch       Date:  2018-07-21       Impact factor: 4.064

10.  Lysophosphatidic Acid Upregulates Laminin-332 Expression during A431 Cell Colony Dispersal.

Authors:  Hironobu Yamashita; Manisha Tripathi; Jerome Jourquin; Yoonseok Kam; Shanshan Liu; Brandy Weidow; Vito Quaranta
Journal:  J Oncol       Date:  2010-08-25       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.